These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 861998)

  • 21. [The pharmacodynamics of hepatic protectors from the lady's-thistle (Silybum marianum)].
    Rumiantseva ZhN
    Vrach Delo; 1991 May; (5):15-9. PubMed ID: 1866906
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of carsil and legalon in treating chronic liver diseases].
    Brailski Kh; Chernev K; Etŭrska M; Donov M; Velev G
    Vutr Boles; 1986; 25(3):43-9. PubMed ID: 3765578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [2 years' experience with combined therapy of symptomatic liver porphyria using pyrimethamine and chloroquine].
    Kaláb M; Cervinka J; Kotal P; Jirsa M; Kordac V; Marecek Z; Soldátová H; Papezová P
    Cas Lek Cesk; 1988 Mar; 127(10):305-9. PubMed ID: 3365727
    [No Abstract]   [Full Text] [Related]  

  • 24. [Diurnal rhythm of exertion of various types of porphyrins in symptomatic hepatic porphyria (author's transl)].
    Martásek P; Jirsa M; Kordac V
    Cas Lek Cesk; 1981 Oct; 120(41):1255-7. PubMed ID: 7201346
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experience with the therapy of symptomatic liver porphyria using a combination of antimalarial agents--chloroquine with pyrimethamine].
    Zoubek V; Martásek P; Kordac V
    Cas Lek Cesk; 1987 Feb; 126(6):170-3. PubMed ID: 3815471
    [No Abstract]   [Full Text] [Related]  

  • 26. [Legalon in the complex treatment of patients with hepatic stasis in chronic circulatory insufficiency].
    Krylov AA
    Vrach Delo; 1984 Mar; (3):22-3. PubMed ID: 6719894
    [No Abstract]   [Full Text] [Related]  

  • 27. [Silymarin, a membranotropic drug: clinical and experimental observations].
    De Martiis M; Fontana M; Sebastiani F; Parenzi A
    Clin Ter; 1977 May; 81(4):333-62. PubMed ID: 880785
    [No Abstract]   [Full Text] [Related]  

  • 28. [Blood groups ABO in the symptomatic hepatic porphyria (author's transl)].
    Kordac V; Semrádová M
    Sb Lek; 1975 Dec; 77(12):353-7. PubMed ID: 1198048
    [No Abstract]   [Full Text] [Related]  

  • 29. [Influence of silymarin and (+)-cyanidanol-3 on the HCB-induced porphyria in rats (author's transl)].
    Thier W; Bolsen K; Goerz G
    Z Gastroenterol; 1982 Jan; 20(1):40-6. PubMed ID: 7064495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Silymarin and various problems of current therapy of chronic liver diseases].
    Fassati P; Fassati M
    Cas Lek Cesk; 1973; 112(28):865-9. PubMed ID: 4720441
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of a water-soluble derivative of silymarin on morphological and functional alterations of mouse hepatocytes induced by Frog Virus 3 (author's transl)].
    Gendrault JL; Steffan AM; Elharrar M; Kirn A
    Arzneimittelforschung; 1979; 29(5):786-91. PubMed ID: 582977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
    Deák G; Müzes G; Láng I; Niederland V; Nékám K; Gonzalez-Cabello R; Gergely P; Fehér J
    Orv Hetil; 1990 Jun; 131(24):1291-2, 1295-6. PubMed ID: 2195425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HLA system in symptomatic hepatic porphyria (author's transl)].
    Cervinka J; Kaláb M; Kordac V
    Cas Lek Cesk; 1981 Nov; 120(46):1408-11. PubMed ID: 7317925
    [No Abstract]   [Full Text] [Related]  

  • 34. [Toxic occupational liver diseases. Therapeutic effects of silymarin].
    Boari C; Montanari FM; Galletti GP; Rizzoli D; Baldi E; Caudarella R; Gennari P
    Minerva Med; 1981 Oct; 72(40):2679-88. PubMed ID: 7290471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alcoholic hepatopathy. Aspects of drug therapy].
    Del Dotto M; Neri D
    G Clin Med; 1982 Apr; 63(4):228-36. PubMed ID: 7128979
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sylimarine in the treatment of chronic hepatitis].
    Sawaryn T; Szymoński K; Machalska M
    Przegl Epidemiol; 1977; 31(4):445-50. PubMed ID: 607279
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapy of hepatic diseases in ambulatory medicine. Multicenter studies].
    Martines G; Mingrino GC; Cagnetta G; Copponi V
    Clin Ter; 1980 Jan; 92(1):33-58. PubMed ID: 7449307
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients].
    Trinchet JC; Coste T; Lévy VG; Vivet F; Duchatelle V; Legendre C; Gotheil C; Beaugrand M
    Gastroenterol Clin Biol; 1989; 13(2):120-4. PubMed ID: 2707520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Silymarin in pregnancy and during hormonal contraceptive treatment. Blood chemistry and ultrastructural findings in the experimental model].
    Martines G; Piva M; Copponi V; Cagnetta G
    Arch Sci Med (Torino); 1979; 136(3):443-54. PubMed ID: 549550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of the administration of silymarin on serum lipid levels].
    Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
    Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.